41 results
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
operates. Any changes in tax laws could have an adverse impact on its financial results.
Environmental, social and corporate governance (“ESG”) issues
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability
6-K
EX-99.3
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
, causing problems in social interaction and communication. The term “spectrum” in autism spectrum disorder refers to the wide range of symptoms
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
restrictive, charging fees or altering its algorithms that determine the placement, display and accessibility of search results and social media updates … or customer support, especially on blogs, social media websites or our sites, could rapidly and severely diminish consumer views of our products
F-1
EX-10.7
cldbpcp ib6cug
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-99.1
ou7 jl844
29 Jan 24
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
4:00pm
6-K
EX-4.1
f5br9op u69bjo
28 Nov 23
Report of Foreign Private Issuer
4:01pm
6-K
EX-99.1
yejfkfhyugzb4h
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-4.1
5wztt xgpm
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-99.2
ovkocv5aq7
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
hcf22b70tivuhg
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
EX-99.1
3cnbetxti 2nye
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
0ml2pa7p8 ra
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-10.3
as1qm39bfdmva00
4 Apr 23
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
7:07am
6-K
EX-99.1
j2j2chbs mtf
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.3
sw7ycopfoqcj74ma9065
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.1
dpn9k 8uv7p8
11 Aug 22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:42am
6-K
EX-99.1
b8hgnp4uwsh
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am